Studies about Copeptin
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
https://www.kidney-international.org/article/S0085-2538(19)30041-9/abstract >
Additional Info
- Indication: Nephrology
- Authors: Gansevoort R, van Gastel M, Chapman A, Blais J, Czerwiec F, Higashihara E, Lee J, Ouyang J, Perrone R, Stade K, Torres V, and Devuyst O
- Source: https://doi.org/10.1016/j.kint.2018.11.044
Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome
The combined copeptin/cTN testing has the potential to save costs and staff time in acute
care and for the entire hospital stay. The primary explanations for these findings are early
identification and ruling out patients without AMI along with the associated reduced need for
acute medical treatment.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202133 >
Additional Info
- Indication: Cardiology
- Authors: Thomas Reinhold, Evangelos Giannitsis, Martin Moeckel, Lutz Frankenstein, Mehrshad Vafaie, Joern O. Vollert, Anna Slagman
- Source: https://doi.org/10.1371/journal.pone.0202133
A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus
The direct measurement of hypertonic saline–stimulated plasma copeptin had greater diagnostic accuracy than the water-deprivation test in patients with hypotonic polyuria.
https://www.nejm.org/doi/full/10.1056/NEJMoa1803760
Additional Info
- Indication: Electrolyte Disorders
- Authors: Wiebke Fenske, M.D., Ph.D., Julie Refardt, M.D., Irina Chifu, M.D., Ingeborg Schnyder, M.D., Bettina Winzeler, M.D., Juliana Drummond, M.D., Antônio Ribeiro-Oliveira, Jr., M.D., Ph.D., Tilman Drescher, M.D., Stefan Bilz, M.D., Deborah R. Vogt, Ph.D., Uwe Malzahn, Ph.D., Matthias Kroiss, M.D., Ph.D., Emanuel Christ, M.D., Ph.D., Christoph Henzen, M.D., Stefan Fischli, M.D., Anke Tönjes, M.D., Beat Mueller, M.D., Jochen Schopohl, M.D., Jörg Flitsch, M.D., Georg Brabant, M.D., Martin Fassnacht, M.D., and Mirjam Christ-Crain, M.D., Ph.D.
- Source: N Engl J Med 2018; 379:428-439 DOI: 10.1056/NEJMoa1803760
Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population
High copeptin levels are associated with the development and the progression of CKD in the general population. Intervention studies are needed to assess the potential beneficial effect on kidney health in the general population of reducing vasopressin secretion or action.
https://doi.org/10.1172/jci.insight.121479 >
Additional Info
- Indication: Nephrology
- Authors: Boustany R, Tasevska I, Meijer E, M. Kieneker L,Enhörning S, Lefèvre G, Mohammedi Kl,1, Marre M, Fumeron F, Balkau B, Bouby N, Bankir L, Bakker S, Roussel R, Melander O, Gansevoort RT and Velho G
- Source: JCI Insight. 2018;3(13):e121479.
Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
Copeptin (the C-terminal glycoprotein of the precursor AVP peptide) is an accurate surrogate marker of AVP release that is stable and easily measured by immunoassay. Cohort studies show that serum copeptin is correlated with disease severity in ADPKD, and predicts future renal events [decline in renal function and increase in total kidney volume (TKV)].
https://www.ncbi.nlm.nih.gov/pubmed/29527508 >
Additional Info
- Indication: Nephrology
- Authors: Tasneem M, Mannix C, Wong A, Zhang J and Rangan G
- Source: World J Nephrol 2018;7 (2),Mar 6: 51-57
- Access: Open Access
